Accepted abstracts for the 2024 AADSM Annual Meeting explore enhanced health outcomes in OSA treatment with oral appliances and reduced staining in medical-grade class VI devices.
Summary: ProSomnus Inc announced the acceptance of two scientific abstracts for presentation at the 2024 American Academy of Dental Sleep Medicine annual meeting. The first study shows that precision oral appliance therapy significantly reduces sleep apnea severity, with sleep apnea-specific hypoxic burden (SASHB) providing a more meaningful assessment than apnea-hypopnea index (AHI). The second study demonstrates that medical-grade class VI devices have lower staining, indicating potentially reduced bacterial colonization and health risks.
Key Takeaways:
- Two ProSomnus scientific abstracts were selected for presentation at the 2024 AADSM annual meeting.
- The first abstract shows that precision oral appliance therapy reduces sleep apnea severity, with SASHB offering a better assessment than AHI.
- The second abstract highlights that medical grade Class VI devices have significantly lower staining, suggesting reduced bacterial colonization.
ProSomnus Inc, a manufacturer of oral appliance therapy for obstructive sleep apnea (OSA), announced the acceptance of two scientific abstracts for presentation at the 2024 American Academy of Dental Sleep Medicine annual meeting in New Orleans.
Health Outcomes of Oral Appliance Therapy in OSA
One abstract selected (#19) is titled “Assessing health outcomes when treating obstructive sleep apnea with mandibular protruding appliances” by Erin Mosca, PhD, Joshua Grosse, MMath, and John Remmers, MD.
Data from three prospective clinical studies with a pooled sample size of 134 were analyzed to assess the relationship between apnea-hypopnea index (AHI), a frequency-based metric, and sleep apnea-specific hypoxic burden (SASHB), a metric that captures the risk associated with OSA.
Precision oral appliance therapy significantly reduced AHI and SASHB in all severities of OSA. 76% of study participants achieved therapeutic success when it was defined as AHI <10/h, whereas 94% achieved therapeutic success when it was defined as SASHB <60% min/h.
AHI appears to misclassify some individuals as therapeutic failures to precision oral appliance therapy despite their having an SAHSB below the threshold of increased risk; therefore, SASHB likely provides a more meaningful assessment of OSA treatment response than AHI as it accounts for the risk associated with the disease.
“The research indicates that judging outcome using sleep apnea-specific hypoxic burden reveals that the traditional methods are inappropriately restrictive,” says Remmers, chief scientist for ProSomnus Sleep Technologies, in a release. “Efficacy of oral appliance therapy is higher than that previously understood when a predictor of long-term clinical outcome is used.”
Class VI Devices Show Superior Performance in Reducing Staining
The second abstract selected (#32) is titled “Medical grade class VI devices demonstrate statistically significantly lower mean staining than other devices tested” by Len Liptak, MBA, Mark Murphy, DDS, ABDSM, and Sung Kim.
Data from this investigation evaluates the staining profile of seven sleep apnea devices. Various previous independent studies establish material staining as a surrogate for bacteria colonization and health risk. Devices made from medical grade class VI material (ProSomnus EVO and ProSomnus EVO [PH]) demonstrated statistically significantly lower staining than the four other oral devices tested and were the only two devices in the study to exhibit less staining than a CPAP mask.
“These two scientific abstracts demonstrate ProSomnus’s commitment to investigating topics, in this case health outcomes and patient safety, that are important to sleep physicians, sleep dentists and, ultimately, patients with OSA,” says Liptak, CEO of ProSomnus Sleep Technologies, in a release. “This type of research is intended to help sleep healthcare providers evaluate non-CPAP treatment options for OSA, particularly for those patients who refuse or terminate CPAP therapy.”
Photo caption: ProSomnus EVO
File photo
